A convergence of cfDNA methylation analysis, multi-omics integration, and artificial intelligence is transforming cancer screening. From the PATHFINDER 2 trial showing a seven-fold increase in cancer detection to the PROMISE…
🧬 Cellular Reprogramming Enters Human Trials — Life Biosciences has launched the first FDA-approved partial de-aging trial, translating Sinclair's epigenetic reprogramming research from animal models to human medicine. 🧠Gut-Brain Axis Reverses Memory Loss — Stanford's Nature study shows that correcting age-related gut bacteria shifts restores youthful cognitive performance by reactivating vagus nerve signaling to the hippocampus. 🤖 AI Drug Discovery Reaches Clinical Scale — 173+ AI-designed drug candidates are now in clinical trials, and longevity medicine is being advised to prepare for AI therapeutics to arrive in clinical practice imminently. 🦠Gut Microbiome as Active Immune Regulator — New research reveals gut bacteria actively inject proteins into cells to modulate immunity, and a microbiome-derived molecule doubled lung cancer immunotherapy response rates in mice. 😴 Circadian Fragmentation Doubles Dementia Risk — A large Neurology journal study found that weak or late-peaking daily activity rhythms more than double the risk of dementia, making circadian optimization a key prevention target.
A landmark UK Biobank study of 60,977 people found that sleep regularity is a stronger predictor of mortality than sleep duration, reducing all-cause death risk by 30 percent. Combined with…
Modern metabolic science, continuous glucose monitors, and wearable technology are confirming what ancient healers understood for millennia: optimal health comes down to mastering the fundamentals of nutrition, breath, recovery, and…
A landmark clinical trial published in Nature Aging shows that urolithin A, a natural mitophagy activator, rejuvenated immune cell populations in middle-aged adults in just 28 days. The MitoImmune trial…
A generative AI-designed drug has delivered clinical proof in a Phase IIa trial, while new biological age clocks and microbiome science are completing the precision longevity toolkit. Here is what…
The first human trial of partial epigenetic reprogramming has launched, an AI platform published in Cell is accelerating longevity drug discovery, and a landmark NEJM trial proves cardiovascular primary prevention…
ARK Invest dumped $87 million in Nvidia and Meta last week and redirected capital into Tempus AI, GeneDx Holdings, CRISPR Therapeutics, and other healthcare AI and genomics companies. The signal…
A meta-analysis of 385,541 people finds that high ultra-processed food consumption raises depression risk by 44 percent and anxiety risk by 48 percent. New research on the gut-brain axis, neuroinflammation,…
Three landmark breakthroughs in longevity reprogramming research 2026 are reshaping what science knows about human aging. An AI-designed drug proves itself in clinical trials, the first human epigenetic reprogramming trial…
Zach RobertsSign up for personalized wellness coaching and the Daily Discovery Newsletter.